國立高雄大學圖資館 |

語系: 繁體中文

說明(常見問題)

圖資館首頁

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Engineering a heterologous mevalonat...

Pitera, Douglas Joseph.

Engineering a heterologous mevalonate pathway for the production of isoprenoids in Escherichia coli.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Engineering a heterologous mevalonate pathway for the production of isoprenoids in Escherichia coli.
作者:	Pitera, Douglas Joseph.
面頁冊數:	257 p.
附註:	Adviser: Jay D. Keasling.
附註:	Source: Dissertation Abstracts International, Volume: 67-08, Section: B, page: 4565.
Contained By:	Dissertation Abstracts International67-08B.
標題:	Biology, Microbiology.
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3228461
ISBN:	9780542826276

Engineering a heterologous mevalonate pathway for the production of isoprenoids in Escherichia coli.
Pitera, Douglas Joseph.

Engineering a heterologous mevalonate pathway for the production of isoprenoids in Escherichia coli. - 257 p.

Adviser: Jay D. Keasling.

Thesis (Ph.D.)--University of California, Berkeley, 2006.

A major obstacle to efficient microbial biosynthesis of isoprenoids is the production of the universal isoprenoid precursors isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP). The biosynthesis of these precursors is highly regulated in all organisms, and previous research on increasing the in vivo supply has focused on engineering a host's native isoprenoid biosynthesis pathway to avoid known regulation.

ISBN: 9780542826276Subjects--Topical Terms:

226920
Biology, Microbiology.

Engineering a heterologous mevalonate pathway for the production of isoprenoids in Escherichia coli.
LDR:03821nmm _2200313 _450 001 180649
005 20080111103806.5
008 090528s2006 eng d
020 $a 9780542826276
035 $a 00311674
040 $a UMI $c UMI
100 0 $a Pitera, Douglas Joseph. $3 264227
245 1 0 $a Engineering a heterologous mevalonate pathway for the production of isoprenoids in Escherichia coli.
300 $a 257 p.
500 $a Adviser: Jay D. Keasling.
500 $a Source: Dissertation Abstracts International, Volume: 67-08, Section: B, page: 4565.
502 $a Thesis (Ph.D.)--University of California, Berkeley, 2006.
520 # $a A major obstacle to efficient microbial biosynthesis of isoprenoids is the production of the universal isoprenoid precursors isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP). The biosynthesis of these precursors is highly regulated in all organisms, and previous research on increasing the in vivo supply has focused on engineering a host's native isoprenoid biosynthesis pathway to avoid known regulation.
520 # $a By engineering E. coli for high level production of isoprenoids, we demonstrate that balancing carbon flux through the engineered biosynthetic pathway is a key determinant in optimizing isoprenoid biosynthesis in microbial hosts.
520 # $a Expression of the heterologous mevalonate pathway circumvented native regulation of isoprenoid biosynthesis in E. coli, by providing a second, unregulated route to the isoprenoid precursors. However, initial optimization efforts demonstrated that unregulated carbon flux through the pathway is detrimental to both production and cell growth. Gene titration studies and metabolite profiling linked growth inhibition phenotypes with the accumulation of pathway intermediates, 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA), and the isoprenyl pyrophosphates, IPP, DMAPP, and farnesyl pyrophosphate. Further study of growth inhibited cells through metabolite and mRNA analysis suggested that the accumulation of HMG-CoA caused an inhibition in the early steps of E. coli's fatty acid biosynthetic pathway. By modulating expression of HMG-CoA reductase and amorphadiene synthase, the pathway bottlenecks were eliminated, growth inhibition was alleviated and production increased. The synthetic mevalonate pathway operons were further optimized by laboratory evolution.
520 # $a Isoprenoids are a highly diverse class of natural products from which numerous commercial chemicals and medicines are derived. Although these compounds are highly valuable in medicine and industry, their production often either suffers from low yields for those molecules derived from natural sources or requires complex and inefficient synthetic routes. Engineering metabolic pathways to produce large quantities of complex isoprenoids in a tractable microbial host presents an attractive alternative to extraction from environmental sources or chemical syntheses.
520 # $a To better address this limitation, we have taken the novel approach of engineering Escherichia coli to over-produce IPP and DMAPP by cloning and expressing the heterologous mevalonate isoprenoid pathway from Saccharomyces cerevisiae. When co-expressed with a condon-optimized amorphadiene synthase, this system successfully demonstrated high-level production of terpenes such as amorpha-4,11-diene, the sesquiterpene olefin precursor to the antimalarial drug artemisinin.
590 $a School code: 0028.
650 # 0 $a Biology, Microbiology. $3 226920
650 # 0 $a Engineering, Chemical. $3 226989
690 $a 0410
690 $a 0542
710 0 # $a University of California, Berkeley. $3 212474
773 0 # $g 67-08B. $t Dissertation Abstracts International
790 $a 0028
790 1 0 $a Keasling, Jay D., $e advisor
791 $a Ph.D.
792 $a 2006
856 4 0 $u http://libsw.nuk.edu.tw:81/login?url=http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3228461 $z http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3228461